PATENT CLAIM ANALYSIS

Application Number: 15750056
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "465000"]

Abstract:
The present disclosure is directed to compositions comprising blended materials comprising a substantially crystalline HCV nucleotide polymerase inhibitor; a first solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients; and a second solid dispersion formulation, which comprises an HCV NS3 inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients. The present disclosure is also directed to oral dosage forms, such as tablets or capsules comprising the disclosed blended compositions comprising the disclosed solid dispersion formulations, and the methods for making these solid dispersion formulations and pharmaceutical compositions.

Claim (Index 14):
A process for preparing an oral dosage form, comprising\n 1) preparing a first blended material by\n a) preparing a first solid dispersion formulation by spray drying, extruding or milling to form particles, said first solid dispersion formulation comprising\n (i) dimethyl ((2S,2\u2032S)-((2S,2\u2032S)-2,2\u2032-(5,5\u2032-((S)-6-(2-cyclopropylthiazol-5-yl)-1-fluoro-6H-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate (Compound II): \n \n or a pharmaceutically acceptable salt thereof;\n (ii) one or more pharmaceutically acceptable polymers or a mixture thereof; and (iii) optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and wherein Compound II and the one or more surfactants are dispersed in a polymer matrix formed by the one or more pharmaceutically acceptable polymers; and b) optionally blending the first solid dispersion formulation with one or more of a diluent, disintegrant, salt, lubricant, and glidant, and c) optionally granulating to form a first blended material; \n 2) preparing a second blended material by\n a) preparing a second solid dispersion formulation by spray drying, extruding or milling to form particles, said second solid dispersion formulation comprising\n (i) (1aR,5S,8S,10R,22aR)\u2014N-[(1R,2S)-1-[(cyclopropylsulfonamido)carbonyl]-2-ethenylcyclopropyl]-14-methoxy-5-(2-methylpropan-2-yl)-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide hydrate (Compound III): \n \n \n or a pharmaceutically acceptable salt thereof,\n (ii) one or more pharmaceutically acceptable polymers or a mixture thereof, and (iii) optionally one or more pharmaceutically acceptable surfactants or a mixture thereof, wherein Compound III and the one or more surfactants are dispersed in a polymer matrix formed by the one or more pharmaceutically acceptable polymers; b) optionally blending the second solid dispersion formulation with one or more of a diluent, disintegrant, salt, lubricant, and glidant, and c) optionally granulating to form a second blended material; \n 3) blending Compound I, the first blended material, the second blended material, and optionally one or more of a diluent, disintegrant, salt, lubricant, and glidant and optionally granulating to provide a blended composition; and \n 4) compressing the particles into a tablet or filling into a capsule.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 88.0
- Lexical Diversity: 2.72881
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15128714', '15607825', '15178164', '13156783', '14006032']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7245565039902764
- 35 USC 102 Novelty (BERT): 0.5045694813235764
- Combined Prediction Score: 0.7025578017236065
- Mean Citation Score: 263.070626
- Max Citation Score: 272.1288
- Similarity Product: 197.3736437430381

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test